Menu
Search
|

Menu

Close
X

Vertex Pharmaceuticals Inc VRTX.OQ (NASDAQ Stock Exchange Global Select Market)

182.83 USD
-4.65 (-2.48%)
As of 3:39 PM GMT
chart
Previous Close 187.48
Open 184.64
Volume 136,205
3m Avg Volume 578,819
Today’s High 185.00
Today’s Low 181.97
52 Week High 195.81
52 Week Low 144.15
Shares Outstanding (mil) 252.12
Market Capitalization (mil) 39,103.64
Forward P/E 150.12
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.88 Mean rating from 24 analysts

KEY STATS

Revenue (mm, USD)
FY18
3,048
FY17
2,489
FY16
1,702
EPS (USD)
FY18
2.073
FY17
1.048
FY16
-0.459
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
150.12
32.54
Price to Sales (TTM)
vs sector
18.35
8.39
Price to Book (MRQ)
vs sector
23.27
5.27
Price to Cash Flow (TTM)
vs sector
118.96
24.12
Total Debt to Equity (MRQ)
vs sector
34.02
16.02
LT Debt to Equity (MRQ)
vs sector
32.93
11.35
Return on Investment (TTM)
vs sector
12.80
13.82
Return on Equity (TTM)
vs sector
19.56
15.25

EXECUTIVE LEADERSHIP

Jeffrey Leiden
Chairman of the Board, President, Chief Executive Officer, Since 2012
Salary: $1,300,000.00
Bonus: --
Paul Silva
Interim Chief Financial Officer, Senior Vice President, Corporate Controller, Since 2019
Salary: --
Bonus: --
Charles Milstein
Executive Vice President, Chief Legal and Administrative Officer, Since 2017
Salary: $694,519.00
Bonus: --
David Altshuler
Executive Vice President - Global Research, Chief Scientific Officer, Since 2015
Salary: $596,731.00
Bonus: --
Stuart Arbuckle
Executive Vice President, Chief Commercial Officer, Since 2012
Salary: $672,885.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

50 Northern Ave
BOSTON   MA   02210-1862

Phone: +1617.3416393

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

SPONSORED STORIES